These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3129240)

  • 21. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.
    Labrie F; Dupont A; Bélanger A; Emond J; Monfette G
    Proc Natl Acad Sci U S A; 1984 Jun; 81(12):3861-3. PubMed ID: 6427777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 23. Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.
    Pavone-Macaluso M; Cacciatore M; Daricello G; Pavone C; Serretta V
    Ann N Y Acad Sci; 1990; 595():328-33. PubMed ID: 2375611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy.
    Langenhuijsen JF; van Lin EN; Hoffmann AL; Spitters-Post I; Alfred Witjes J; Kaanders JH; Mulders PF
    Urol Oncol; 2011; 29(1):52-7. PubMed ID: 19523856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pulmonary toxicity of nilutamide (Anandron). Cooperative evaluation of French Regional Pharmacovigilance Centers].
    Jonville AP; Diot E; Dutertre JP; Autret E
    Therapie; 1992; 47(5):393-7. PubMed ID: 1299978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
    Barthélémy Y; Colombel M; Gasman D; Patard JJ; Chopin D; Abbou CC
    Prog Urol; 1996 Feb; 6(1):93-7. PubMed ID: 8624534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nilutamide pneumonitis: a report on eight patients.
    Pfitzenmeyer P; Foucher P; Piard F; Coudert B; Braud ML; Gabez P; Lacroix S; Mabille JP; Camus P
    Thorax; 1992 Aug; 47(8):622-7. PubMed ID: 1412120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical study of RU 23908 (nilutamide) in prostatic cancer].
    Akaza H; Aso Y; Niijima T; Fuse H; Izaka S; Akimoto S; Shimazaki J; Imai K; Yamanaka H; Kihara K
    Hinyokika Kiyo; 1991 Apr; 37(4):407-20. PubMed ID: 1892002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
    Bélanger A; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
    Hucher M; de Gery A; Bertagna C
    Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
    [No Abstract]   [Full Text] [Related]  

  • 31. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
    Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
    Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate.
    Smith JA; Janknegt RA; Abbou CC; de Gery A
    Eur Urol; 1997; 31 Suppl 3():25-9. PubMed ID: 9101212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
    Migliari R; Scarpa RM; Campus G; De Lisa A; Zucca I; D'Atri M; Serra A; Usai E
    Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):147-53. PubMed ID: 1830407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Indications of antiandrogens in benign hyperplasia of the prostate].
    Benassayag E
    J Urol (Paris); 1995; 101(2):109-10. PubMed ID: 8522854
    [No Abstract]   [Full Text] [Related]  

  • 35. Androgen blockade in prostate cancer.
    Labrie F; Candas B
    Lancet; 2000 Jul; 356(9226):341-2. PubMed ID: 11071217
    [No Abstract]   [Full Text] [Related]  

  • 36. Buserelin in the treatment of prostatic cancer.
    Roila F
    Biomed Pharmacother; 1989; 43(4):279-85. PubMed ID: 2506941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
    Waxman J
    Prog Clin Biol Res; 1989; 303():61-8. PubMed ID: 2528741
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hormonal treatments of prostate cancer].
    Kuhn JM
    Rev Prat; 1990 Nov; 40(25):2357-62. PubMed ID: 2124721
    [No Abstract]   [Full Text] [Related]  

  • 39. Anandron (RU 23908) associated with orchiectomy in stage D prostate cancer. Preliminary results of a randomized, double-blind study.
    Namer M; Amiel J; Toubol J
    Am J Clin Oncol; 1988; 11 Suppl 2():S191-6. PubMed ID: 3071952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lung caught in Nilutamide treatment.
    Lourenço EP; Nzwalo H; Sampaio MR; Brito H
    BMJ Case Rep; 2016 Sep; 2016():. PubMed ID: 27599808
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.